Abstract
Introduction: Dupilumab is a monoclonal antibody approved in the US for patients aged ≥6 years with moderate-to-severe AD inadequately controlled by topical therapies. This analysis evaluates the impact of long-term dupilumab therapy on disease control and treatment satisfaction among US adults with AD from RELIEVE-AD, a prospective, longitudinal patient survey.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
